Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Drops By 41.1%

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPXGet Rating) was the target of a large drop in short interest during the month of July. As of July 15th, there was short interest totalling 38,300 shares, a drop of 41.1% from the June 30th total of 65,000 shares. Currently, 0.5% of the company’s shares are short sold. Based on an average daily volume of 145,500 shares, the short-interest ratio is presently 0.3 days.

Virpax Pharmaceuticals Price Performance

VRPX stock opened at $1.52 on Friday. The stock has a 50-day moving average price of $1.53 and a 200-day moving average price of $1.87. Virpax Pharmaceuticals has a 1-year low of $1.19 and a 1-year high of $36.00.

Virpax Pharmaceuticals (NASDAQ:VRPXGet Rating) last posted its quarterly earnings data on Monday, May 16th. The company reported ($0.44) earnings per share for the quarter.

Insider Buying and Selling

In related news, CEO Anthony P. Mack bought 75,750 shares of the stock in a transaction that occurred on Wednesday, May 18th. The stock was acquired at an average cost of $1.34 per share, with a total value of $101,505.00. Following the transaction, the chief executive officer now directly owns 252,562 shares in the company, valued at $338,433.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders purchased a total of 84,729 shares of company stock valued at $113,401 in the last three months. Insiders own 28.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Citigroup Inc. acquired a new stake in shares of Virpax Pharmaceuticals in the 1st quarter valued at about $27,000. Warberg Asset Management LLC acquired a new stake in shares of Virpax Pharmaceuticals in the 1st quarter valued at about $39,000. Vanguard Group Inc. grew its stake in shares of Virpax Pharmaceuticals by 4.5% in the 1st quarter. Vanguard Group Inc. now owns 341,977 shares of the company’s stock valued at $759,000 after buying an additional 14,672 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in shares of Virpax Pharmaceuticals in the 1st quarter valued at about $348,000. 18.90% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Maxim Group initiated coverage on Virpax Pharmaceuticals in a research report on Thursday, June 9th. They set a “buy” rating and a $4.00 target price for the company.

Virpax Pharmaceuticals Company Profile

(Get Rating)

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.

Recommended Stories

Receive News & Ratings for Virpax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virpax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.